Mesenchymal stromal cells in kidney transplantation
- PMID: 30300159
- DOI: 10.1097/MNH.0000000000000461
Mesenchymal stromal cells in kidney transplantation
Abstract
Purpose of review: Mesenchymal stromal cells (MSC) have emerged as one of the most promising candidates for immunomodulatory cell therapy in kidney transplantation. Here we describe novel insights into the MSC mechanism of action and provide an overview of initial safety and feasibility studies with MSC in kidney transplantation.
Recent findings: Clinical studies of MSC-based cell therapy in kidney transplant recipients demonstrated the safety and feasibility of cell therapy and provide the first encouraging evidence of the efficacy of MSC in enabling the minimization of immunosuppressive drugs. In our initial experience with MSC-based therapy in kidney transplant recipients we carried out extensive clinical and immunological monitoring of MSC-treated patients and found possible biomarkers of MSC immunomodulation in some of them. Based on these biomarkers we identified a patient in whom complete discontinuation of immunosuppression has been achieved safely and successfully.
Summary: Many issues should be addressed before MSC-based therapy becomes a standard treatment protocol for kidney transplantation. A better understanding of the MSC mechanism of action and the identification of biomarkers of response to therapy will inform the rational design of the most effective clinical protocol and the selection of patients amenable to safe immunosuppressive drug withdrawal.
Similar articles
-
Mesenchymal stromal cells to promote solid organ transplantation tolerance.Curr Opin Organ Transplant. 2013 Feb;18(1):51-8. doi: 10.1097/MOT.0b013e32835c5016. Curr Opin Organ Transplant. 2013. PMID: 23254705 Review.
-
Mesenchymal stromal cells for tolerance induction in organ transplantation.Hum Immunol. 2018 May;79(5):304-313. doi: 10.1016/j.humimm.2017.12.008. Epub 2017 Dec 27. Hum Immunol. 2018. PMID: 29288697 Review.
-
Mesenchymal Stromal Cells for Transplant Tolerance.Front Immunol. 2019 Jun 4;10:1287. doi: 10.3389/fimmu.2019.01287. eCollection 2019. Front Immunol. 2019. PMID: 31231393 Free PMC article. Review.
-
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation.Transpl Int. 2013 Sep;26(9):867-78. doi: 10.1111/tri.12132. Epub 2013 Jun 6. Transpl Int. 2013. PMID: 23738760 Clinical Trial.
-
Mesenchymal stromal cells to promote kidney transplantation tolerance.Curr Opin Organ Transplant. 2014 Feb;19(1):47-53. doi: 10.1097/MOT.0000000000000035. Curr Opin Organ Transplant. 2014. PMID: 24257324 Review.
Cited by
-
Effects of single and multiple transplantations of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice.J Ovarian Res. 2021 Sep 15;14(1):119. doi: 10.1186/s13048-021-00871-4. J Ovarian Res. 2021. PMID: 34526090 Free PMC article.
-
Cell-based regenerative medicine for renovascular disease.Trends Mol Med. 2021 Sep;27(9):882-894. doi: 10.1016/j.molmed.2021.06.004. Epub 2021 Jun 25. Trends Mol Med. 2021. PMID: 34183258 Free PMC article. Review.
-
Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells.World J Stem Cells. 2021 Aug 26;13(8):971-984. doi: 10.4252/wjsc.v13.i8.971. World J Stem Cells. 2021. PMID: 34567420 Free PMC article. Review.
-
Novel Methods to Mobilize, Isolate, and Expand Mesenchymal Stem Cells.Int J Mol Sci. 2021 May 27;22(11):5728. doi: 10.3390/ijms22115728. Int J Mol Sci. 2021. PMID: 34072061 Free PMC article.
-
When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease.Front Med (Lausanne). 2021 Sep 20;8:728496. doi: 10.3389/fmed.2021.728496. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34616756 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials